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1. Introduction 
The global prevalence of diabetes among adults over 18 years of age 
has risen from 4.7% in 1980 to 8.5% in 2014. Diabetes-related 
healthcare expenditure accounts for 10% of the total healthcare costs 
but it is estimated to increase by 70% over the next 25 years leading to 
a serious societal and economic burden. Diabetes complications are 
responsible for the majority of the associated costs. Hyperglycemia-
induced endothelial dysfunction is the major contributor to the 
development of vascular disease in diabetes mellitus. The major 
pathway that is responsible for endothelial damage is glucose-induced 
oxidative stress in diabetes.  
2. Aims 
The glucose-induced cell damage is mediated by oxidative stress in 
endothelial cells, and according to the unifying hypothesis  
mitochondrial reactive oxygen species (ROS) production acts as an 
upstream player in this process. Reactive oxygen species are produced 
by the respiratory chain (complexes I and III) in the mitochondria via 
directly transferring electrons to oxygen leaving behind extra protons 
in the intermembrane space.  
To find potential inhibitors of hyperglycemic endothelial damage we 
pursued the following Specific Aims:  
1. Establish a cell culture model of hyperglycemia-induced 
endothelial injury that is characterized by mitochondrial 
overproduction of ROS and is applicable for medium 
throughput cell-based drug screening 
2. Screen the currently available clinical drugs and similar 
biologically active compounds to identify inhibitors of the 
glucose-induced mitochondrial ROS production in endothelial 
cells 
3. Determine the mechanism of action of selected hit compounds 
against hyperglycemic mitochondrial ROS production.  
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3. Methods 
 
We conducted a phenotypic screen to identify compounds that inhibit 
the mitochondrial ROS production induced by elevated extracellular 
glucose in cultured b.End3 endothelial cells. We tested a focused 
library consisting of 6,766 compounds, which included clinical-stage 
drugs, biologically active compounds with defined pharmacological 
activity and natural compounds.  
Cellular and mitochondrial ROS production was measured by kinetic 
assays based on the use of mitochondrial superoxide and H2O2-
sensitive probes MitoSOX Red and 5-(and-6)-chloromethyl-2',7'-
dichlorodihydro fluorescein diacetate, acetyl ester (CM-H2DCFDA). 
Mitochondrial oxidant production was also evaluated in situ using 
fluorescence microscopy following dual staining with MitoSOX Red 
and mitoTracker, supplemented with nuclear staining with Hoechst 
33342. The mitochondrial membrane potential was measured after 
loading the cells with the mitochondrial membrane potential probe JC-
1 dye. Oxidative damage was evaluated at the DNA, RNA and protein 
levels using the Comet assay, immunofluorescent labeling for 8-
hydroxy-guanosine and via the Oxyblot method.  
Cellular viability was determined using nuclear staining with Hoechst 
33342 and the cellular metabolism was explored using thiazolyl blue 
tetrazolium (MTT) and lactate dehydrogenase (LDH) assays. Cellular 
oxygen consumption and acid production rates were also determined 
utilizing extracellular Flux Analysis (Seahorse, Billerica, MA).  
Gene expression changes were determined by real-time PCR-based 
assays or macroassays at the mRNA level, and by Western blotting at 
the protein level. siRNA mediated gene silencing was used to suppress 
the expression of drug target UCP2 in separate experiments.  
Isolated mitochondria assays and selected respiratory complex activity 
assays were used to specifically explore the positive effect of H2S 
donors.  
The protective effect on vascular function was also evaluated using 
vessel bath (myography) experiments either in diabetic samples 
treated in vivo or in vessels exposed to high glucose ex vivo.  
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4. Results 
4.1. Hyperglycemia induces ROS production and oxdiative injury 
in microvascular endothelial cells  
 
Extended hyperglycemic exposure induced a progressive increase in 
the mitochondrial ROS production in microvascular endothelial cells. 
The glucose-induced ROS production was associated with metabolic 
changes in the cells, but no alteration was detected in the expression 
of genes related to mitochondrial ATP production. When exposed to 
hyperglycemia, the cells showed a progressive increase in the 
mitochondrial MTT conversion indicating the stimulation of aerobic 
metabolism and oxidative phosphorylation (OXPHOS). On the other 
hand, no change was detectable in the anaerobic metabolism as 
measured by the cellular LDH activity. Similar to the changes in the 
mitochondrial metabolism, a progressive increase was detectable in 
the mitochondrial membrane potential coinciding with the increase in 
the mitochondrial ROS production. Furthermore, cytoplasmic sources 
of ROS generation were also stimulated in the cells.  
The cells maintained a stable energy level in hyperglycemia for 7 days 
but a decline was detectable afterwards. Despite the elevated 
membrane potential, mitochondria failed to generate the necessary 
energy to meet the basal ATP requirement of the cells. Since no 
suppression was detectable in the level of assembled respiratory 
complexes, the metabolic failure might be explained by a functional 
deficit in the mitochondrial electron transfer (or in the chemiosmotic 
coupling).  
In summary, the increased glucose load led to mitochondrial 
hyperpolarization that may serve as a promoter of increased ROS 
generation in microvascular endothelial cells and many features of this 
cellular injury model closely match the changes seen in diabetes.  
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4.2. Cell-based screening for inhibitors of hyperglycemia-induced 
mitochondrial ROS production in endothelial cells 
 
In the above cell-based assay, we tested a library of biologically active 
compounds against mitochondrial ROS production induced by high 
glucose exposure. The data sets of cellular ROS production and 
viability values showed Gaussian distribution and the majority of test 
compounds had no effect on mitochondrial ROS generation in the 
primary screen. Non-toxic compounds inhibiting the hyperglycemia-
induced ROS production by more than 25% at 3 µM were selected as 
hits and were re-tested in replicates to confirm the antioxidant activity. 
Compounds passing the hit confirmation studies included steroids, 
non-steroidal anti-inflammatory agents, antioxidants, mitochondrial 
uncouplers and antimetabolites.  
From the multiple classes of pharmacologically active compounds 
identified in the screen, we chose to focus our subsequent studies on 
paroxetine (a clinically used antidepressant compound), 
glucocorticoid steroids and the novel mitochondrial H2S donor 
compounds AP39 and AP123. The hypothesized molecular targets of 
these drugs are shown on the Figure. 
4.3. Characterization of the mode of action of hit compounds  
4.3.1. Paroxetine acts as a  mitochondrial superoxide scavenger in 
hyperglycemic endothelial cells Paroxetine	 showed	 preference	 to	 inhibit	 mitochondrial	 ROS	production,	which	was	a	unique	feature	of	this	compound	among	selective	 serotonin	 reuptake	 inhibitors.	 The	 effect	 of	 paroxetine	depended	 on	 an	 immediate	 mode	 of	 action	 and	 the	 drug	 also	remained	 effective	 against	 the	 hyperglycemia-induced	mitochondrial	ROS	generation	in	human	endothelial	cells.		
Paroxetine had no effect on the oxygen consumption rate in isolated 
mitochondria or in whole cells and it did not affect the cellular ATP 
content. Paroxetine was also effective against superoxide in a xanthine 
oxidase-based cell-free assay suggesting a direct scavenging function.  
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The superoxide neutralizing effect of paroxetine translated into 
measurable benefits in hyperglycemia. DNA fragmentation, the 
formation of 8-hydroxy-guanosine (an indicator of oxidative damage 
to the RNA) and oxidation of proteins were all attenuated by 
paroxetine, indicative of the ability of paroxetine to reduce the 
downstream consequences of mitochondrial ROS production. 
The protective effect of paroxetine on hyperglycemia- and diabetes-
induced endothelial dysfunction was tested in vascular rings. 
Paroxetine maintained the normal endothelium-dependent relaxant 
responsiveness of hyperglycemic vessels and similarly prevented the 
diabetes-induced impairment of the endothelium-dependent 
relaxations ex vivo. 
	
Figure. Potential targets of  hit compounds against 
hyperglycemia-induced ROS produciton. Paroxetin acts as direct 
superoxide scavenger, glucocorticoids induce UCP2 expression, H2S 
donor compounds act as electron donors.  
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4.3.2. Glucocorticoids reduce the mitochondrial ROS production 
via UCP2 induction in microvascular endothelial cells 
Glucocorticoid steroids inhibited the glucose-induced mitochondrial 
ROS production and emerged as hit compounds in our screen. 
Unexpectedly, the glucocorticoid antagonist mifepristone also 
decreased the hyperglycemia-induced ROS production in 
microvascular endothelial cells and at low micromolar concentrations 
it was more effective than dexamethasone. Both dexamethasone and 
mifepristone normalized the mitochondrial potential, which effect was 
associated with a 10-fold increase in the expression of uncoupling 
protein 2 (UCP2) suggesting that the induction of UCP2 expression 
may be responsible for the steroid-mediated anti-ROS effect in 
microvascular endothelial cells. 
siRNA mediated UCP2 silencing partially blocked the response to 
steroids and also suppressed the ROS-inhibitory effect of 
mifepristone. It also caused an increase in the mitochondrial 
superoxide generation by itself. The reduced level of UCP2 led to an 
increase in the mitochondrial potential and partially blocked the 
membrane potential normalizing effect of mifepristone. Overall, these 
results suggest that UCP2 expression is responsible for the decrease 
induced by glucocorticoid steroids in the hyperglycemic endothelial 
cells. 
Following the steroid-mediated UCP2 induction, higher proton leak 
was measurable in the hyperglycemic cells. UCP2 silencing 
diminished the increase in the proton leak. These results suggest that 
pharmacological induction of UCP2 expression can be achieved in 
select cell populations and in microvascular endothelial cells it causes 
distinct changes in the cellular metabolism. 
4.3.3. Mitochondria-targeted H2S-donor compounds inhibit the 
mitochondrial ROS production via electron donation  
The mitochondrial slow-release H2S donors AP39 and AP123 reduced 
the mitochondrial ROS production and also caused a slight decrease in 
the cellular ROS production. Both compounds significantly reduced 
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the hyperglycemia-induced increase in the mitochondrial membrane 
potential at low nanomolar concentrations. AP39 was more effective 
than AP123 that might be explained by the higher H2S release of 
AP39.  
Mitochondria-targeted H2S donors AP39 and AP123 induced a 
concentration-dependent increase in the cellular ATP content in 
endothelial cells showing a diminished ATP pool after prolonged 
exposure to hyperglycemia.  
The mitochondrial H2S donors improved the coupling efficiency and 
significantly reduced the proton leak as measured by extracellular flux 
analysis that could explain the increased cellular ATP content in the 
cells without a measurable increase in oxygen consumption. No 
change was detectable in the anaerobic metabolism confirming that 
the compounds do not inhibit mitochondrial respiration at the tested 
concentrations.  
To confirm that the action of mitochondrial H2S donors directly 
increase the electron transfer, we performed a Complex II/III activity 
assay. We blocked input from Complex I by rotenone and inhibited 
Complex IV (cytochrome c oxidation) by potassium cyanide and 
measured the activity of complex III. (In the presence of substrate 
succinate, Complex II transfers electrons to ubiquinone that passes 
them to Complex III to reduce cytochrome c.) Both H2S donors 
induced a concentration-dependent increase in complex III activity 
(cytochrome c reduction) at concentrations below 2.5 µM confirming 
that the compounds directly affect the respiratory complex activities. 
We propose that the electron donation step of mitochondrial H2S 
oxidation (as electrons are fed to the quinone pool at the level of 
complex III) and the subsequent oxygen consumption (that occurs at a 
later step of H2S oxidation) may be uncoupled and these compounds 
may preferentially resupply the “lost electrons” to the respiratory 
chain. These results are in agreement with other reports suggesting 
that H2S can act as an electron donor in the electron transport chain. It 
is of note that mitochondrial donors were effective at 1000-fold lower 
concentration than previous, non-targeted H2S donors.  
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5. Conclusions 
 
In conclusion, the current studies have utilized a cell-based screening 
method to identify a number of drugs and drug-like molecules that 
beneficially affect hyperglycemic ROS production in endothelial cells.  
One of these compounds, the antidepressant paroxetine, has been 
tested in a variety of in vitro and in vivo/ex vivo models of 
hyperglycemic endothelial injury and diabetic vascular complications. 
We found that paroxetine shows effect at submicromolar 
concentrations and superoxide scavenging is involved in its mode of 
action against mitochondrial ROS. It is interesting to note that 
paroxetine has previously been shown to afford certain cardiovascular 
benefits in terms of protection from myocardial infarction in humans.  
The antioxidant effect of mifepristone, a glucocorticoid receptor 
antagonist, is associated with mild mitochondrial uncoupling, which is 
achieved by induction of UCP2 expression. This compound was also 
found to be effective in a clinically relevant concentration range.  
Mitochondrial slow release H2S donors also provided protection 
against the prolonged low level oxidative stress induced by 
hyperglycemia in endothelial cells. They increase the electron transfer 
rate at respiratory complex III and have beneficial effect on cellular 
bioenergetics. These compounds showed positive effect in the 
nanomolar concentration range, which is more than two orders of 
magnitude lower than their maximum tolerated concentration, 
suggesting a safer alternative compared to non-targeted H2S donors 
and natural sources.  
The current results may lay the conceptual foundation for future 
exploratory clinical trials in patients with diabetes, with the potential 
ultimate goal of re-purposing for the experimental therapy of diabetic 
complications. However, such studies must be preceded by careful 
investigation of the safety profile of this compound in diabetic 
patients. 
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